All Stories

  1. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling

    Article • The FASEB Journal, June 2019, Federation of American Societies For Experimental Biology (FASEB)

    Mark Hutchinson

  2. Are the protective benefits of vitamin D in neurodegenerative disease dependent on route of administration? A systematic review

    Article • Nutritional Neuroscience, July 2018, Taylor & Francis

    Mark Hutchinson, Lyndsey Collins-Praino

  3. ‘Convergence’ created psychoneuroimmunology, and is needed again to secure the future of the field

    Article • Brain Behavior and Immunity, July 2018, Elsevier

    Mark Hutchinson

  4. Can neuroimmune mechanisms explain the link between ultraviolet light (UV) exposure and addictive behavior?

    Article • Brain Behavior and Immunity, July 2018, Elsevier

    Mark Hutchinson

  5. Toll-like Receptor-4: A New Target for Preterm Labour Pharmacotherapies?

    Article • Current Pharmaceutical Design, May 2018, Bentham Science Publishers

    Professor, Head of Laboratories Jeffrey A Keelan, Mark Hutchinson

  6. Spinal Glial Adaptations Occur in a Minimally Invasive Mouse Model of Endometriosis: Potential Implications for Lesion Etiology and Persistent Pelvic Pain

    Article • Reproductive Sciences, May 2018, SAGE Publications

    Mark Hutchinson

  7. Differential effect of morphine on gastrointestinal transit, colonic contractions and nerve-evoked relaxations in Toll-Like Receptor deficient mice

    Article • Scientific Reports, April 2018, Springer Science + Business Media

    Mark Hutchinson

  8. The importance of knowing you are sick: Nanoscale biophotonics for the ‘other’ brain

    Article • Microelectronic Engineering, February 2018, Elsevier

    Mark Hutchinson

  9. The efficacy of (+)-Naltrexone on alcohol preference and seeking behaviour is dependent on light-cycle

    Article • Brain Behavior and Immunity, January 2018, Elsevier

    Mark Hutchinson

  10. Fluorescence brightness and photostability of individual copper (I) oxide nanocubes

    Article • Scientific Reports, December 2017, Nature

    Mark Hutchinson

  11. Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats

    Article • Behavioural Brain Research, September 2017, Elsevier

    Mark Hutchinson

  12. Graphene quantum dot based “switch-on” nanosensors for intracellular cytokine monitoring

    Article • Nanoscale, January 2017, Royal Society of Chemistry

    Mark Hutchinson

  13. The Importance of Knowing You are Sick: Biophotonics For The 'Other' Brain

    Article • January 2017, Optical Society of America (OSA)

    Mark Hutchinson

  14. Sensitive Cytokine Assay Based on Optical Fiber Allowing Localized and Spatially Resolved Detection of Interleukin-6

    Article • ACS Sensors, December 2016, American Chemical Society (ACS)

    Mark Hutchinson

  15. Hollow core optical fibres made by glass billet extrusion as sensors for Raman spectroscopy

    Article • December 2016, SPIE

    Mark Hutchinson

  16. Hyperspectral imaging of endogenous fluorescent metabolic molecules to identify pain states in central nervous system tissue

    Article • December 2016, SPIE

    Mark Hutchinson

  17. Measurements of vitamin B12 in human blood serum using resonance Raman spectroscopy

    Article • December 2016, SPIE

    Mark Hutchinson

  18. Constriction of the buccal branch of the facial nerve produces unilateral craniofacial allodynia

    Article • Brain Behavior and Immunity, December 2016, Elsevier

    Mark Hutchinson

  19. Nitroxidative Signaling Mechanisms in Pathological Pain

    Article • Trends in Neurosciences, December 2016, Elsevier

    Mark Hutchinson

  20. Shapeshifting photoswitchable azobenzene compounds and their biological applications

    Article • November 2016, SPIE

    Mark Hutchinson

  21. A portable optical fiber probe for in vivo brain temperature measurements

    Article • November 2016, SPIE

    Mark Hutchinson

  22. Novel Toll-like receptor-4 antagonist (+)-naloxone protects mice from inflammation-induced preterm birth

    Article • Scientific Reports, November 2016, Nature

    Mark Hutchinson

  23. Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain

    Article • Pain, November 2016, Wolters Kluwer Health

    Mark Hutchinson

  24. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury

    Article • Brain Behavior and Immunity, November 2016, Elsevier

    Mark Hutchinson, Dr Scott P Falci

  25. Novel imaging tools for investigating the role of immune signalling in the brain

    Article • Brain Behavior and Immunity, November 2016, Elsevier

    Mark Hutchinson

  26. Measurements of vitamin B12 in human blood serum using resonance Raman spectroscopy

    Article • October 2016, Institute of Electrical & Electronics Engineers (IEEE)

    Mark Hutchinson

  27. Measuring and tracking vitamin B12: A review of current methods with a focus on optical spectroscopy

    Article • Applied Spectroscopy Reviews, September 2016, Taylor & Francis

    Mark Hutchinson

  28. Local and Systemic Inflammation in Localized, Provoked Vestibulodynia

    Article • Obstetrics and Gynecology, August 2016, Wolters Kluwer Health

    Mark Hutchinson

  29. The role of Toll-like receptor 4 (TLR4) in cardiac ischaemic-reperfusion injury, cardioprotection and preconditioning

    Article • Clinical and Experimental Pharmacology and Physiology, July 2016, Wiley

    Mark Hutchinson

  30. Portable optical fiber probe for in vivo brain temperature measurements

    Article • Biomedical Optics Express, July 2016, Optical Society of America (OSA)

    Mark Hutchinson

  31. Recent advances in cytokine detection by immunosensing

    Article • Biosensors and Bioelectronics, May 2016, Elsevier

    Mark Hutchinson

  32. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms

    Article • Molecular Cancer Therapeutics, March 2016, American Association for Cancer Research (AACR)

    Mark Hutchinson

  33. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4

    Article • British Journal of Pharmacology, February 2016, Wiley

    Mark Hutchinson

  34. Drug addiction: targeting dynamic neuroimmune receptor interactions as a potential therapeutic strategy

    Article • Current Opinion in Pharmacology, February 2016, Elsevier

    Mark Hutchinson

  35. Hollow-Core Optical Fibers Made by Glass Billet Extrusion as Sensors for Raman Spectroscopy

    Article • January 2016, Optical Society of America (OSA)

    Mark Hutchinson

  36. Chemotherapy-induced gut toxicity and pain: involvement of TLRs

    Article • Supportive Care in Cancer, November 2015, Springer Science + Business Media

    Mark Hutchinson

  37. Toll-Like Receptor 4 Is an Essential Upstream Regulator of On-Time Parturition and Perinatal Viability in Mice

    Article • Endocrinology, October 2015, Endocrine Society

    Mark Hutchinson

  38. Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety

    Article • Headache The Journal of Head and Face Pain, September 2015, Wiley

    Mark Hutchinson, Dr Jacinta Lee Johnson

  39. Amitriptyline pharmacologically preconditions rat hearts against cardiac ischemic–reperfusion injury

    Article • International Journal of Cardiology, July 2015, Elsevier

    Mark Hutchinson

  40. CYP2B6*6allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects

    Article • British Journal of Clinical Pharmacology, June 2015, Wiley

    Mark Hutchinson

  41. Mouse models of mastitis – how physiological are they?

    Article • International Breastfeeding Journal, March 2015, Springer Science + Business Media

    Mark Hutchinson

  42. Alcohol-induced sedation and synergistic interactions between alcohol and morphine: A key mechanistic role for Toll-like receptors and MyD88-dependent signaling

    Article • Brain Behavior and Immunity, March 2015, Elsevier

    Mark Hutchinson

  43. DAT isn’t all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling

    Article • Molecular Psychiatry, February 2015, Nature

    Mark Hutchinson

  44. Select steroid hormone glucuronide metabolites can cause toll-like receptor 4 activation and enhanced pain

    Article • Brain Behavior and Immunity, February 2015, Elsevier

    Mark Hutchinson

  45. Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation

    Article • Translational Psychiatry, November 2014, Nature

    Mark Hutchinson, Dr Jacinta Lee Johnson

  46. Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae

    Article • Neuroscience, November 2014, Elsevier

    Mark Hutchinson

  47. Want more pain? Just add a dash of endotoxin to enhance your clinical pain model

    Article • Brain Behavior and Immunity, October 2014, Elsevier

    Mark Hutchinson

  48. Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder

    Article • Frontiers in Neuroscience, September 2014, Frontiers

    Mark Hutchinson

  49. In vivo veritas: (+)-Naltrexone's actions define translational importance

    Article • Trends in Pharmacological Sciences, September 2014, Elsevier

    Mark Hutchinson

  50. Glial TLR4 signaling does not contribute to opioid-induced depression of respiration

    Article • Journal of Applied Physiology, August 2014, American Physiological Society

    Mark Hutchinson

  51. Inflammatory Mediators in Mastitis and Lactation Insufficiency

    Article • Journal of Mammary Gland Biology and Neoplasia, June 2014, Springer Science + Business Media

    Mark Hutchinson

  52. Reduced Response to the Thermal Grill Illusion in Chronic Pain Patients

    Article • Pain Medicine, April 2014, Oxford University Press (OUP)

    Mark Hutchinson

  53. A concern on comparing ‘apples’ and ‘oranges’ when differences between microglia used in human and rodent studies go far, far beyond simply species: comment on Smith and Dragunow

    Article • Trends in Neurosciences, April 2014, Elsevier

    Mark Hutchinson

  54. Toll-Like Receptor 4 Regulates Lipopolysaccharide-Induced Inflammation and Lactation Insufficiency in a Mouse Model of Mastitis

    Article • Biology of Reproduction, March 2014, Oxford University Press (OUP)

    Mark Hutchinson

  55. Pathological pain and the neuroimmune interface

    Article • Nature Reviews Immunology, February 2014, Nature

    Mark Hutchinson

  56. Immune priming and experimental glaucoma: the effect of prior systemic lipopolysaccharide challenge on tissue outcomes after optic nerve injury

    Article • Clinical and Experimental Ophthalmology, January 2014, Wiley

    Mark Hutchinson

  57. Why is neuroimmunopharmacology crucial for the future of addiction research?

    Article • Neuropharmacology, January 2014, Elsevier

    Mark Hutchinson

  58. Sex differences in mechanical allodynia: how can it be preclinically quantified and analyzed?

    Article • Frontiers in Behavioral Neuroscience, January 2014, Frontiers

    Mark Hutchinson

  59. Discovery of a Novel Site of Opioid Action at the Innate Immune Pattern-Recognition Receptor TLR4 and its Role in Addiction

    Article • January 2014, Elsevier

    Mark Hutchinson

  60. Drug Addiction

    Article • January 2014, Springer Science + Business Media

    Mark Hutchinson

  61. Association of Innate Immune Single-Nucleotide Polymorphisms with the Electroencephalogram During Desflurane General Anaesthesia

    Article • Journal of Molecular Neuroscience, December 2013, Springer Science + Business Media

    Mark Hutchinson

  62. Low-dose endotoxin potentiates capsaicin-induced pain in man: Evidence for a pain neuroimmune connection

    Article • Brain Behavior and Immunity, May 2013, Elsevier

    Mark Hutchinson

  63. Glucuronic acid and the ethanol metabolite ethyl-glucuronide cause toll-like receptor 4 activation and enhanced pain

    Article • Brain Behavior and Immunity, May 2013, Elsevier

    Mark Hutchinson

  64. The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro

    Article • Drug Metabolism and Disposition, April 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Mark Hutchinson

  65. Effect of Chronic Delivery of the Toll-like Receptor 4 Antagonist (+)-Naltrexone on Incubation of Heroin Craving

    Article • Biological Psychiatry, April 2013, Elsevier

    Mark Hutchinson

  66. Erratum

    Article • Expert Review of Neurotherapeutics, March 2013, Taylor & Francis

    Mark Hutchinson

  67. Role of microglia and toll-like receptor 4 in the pathophysiology of delirium

    Article • Medical Hypotheses, December 2012, Elsevier

    Mark Hutchinson

  68. Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment

    Article • Cephalalgia, November 2012, SAGE Publications

    Mark Hutchinson, Dr Jacinta Lee Johnson

  69. Therapeutic Strategies to Treat Alcohol-Related Disorders Targeting Central Immune Signaling

    Article • September 2012, Springer Science + Business Media

    Mark Hutchinson

  70. Increased Responsiveness of Peripheral Blood Mononuclear Cells to In Vitro TLR 2, 4 and 7 Ligand Stimulation in Chronic Pain Patients

    Article • PLoS ONE, August 2012, PLOS

    Mark Hutchinson

  71. Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement

    Article • Journal of Neuroscience, August 2012, Society for Neuroscience

    Mark Hutchinson

  72. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model

    Article • Journal of Neurochemistry, July 2012, Wiley

    Mark Hutchinson

  73. The Effects of Pregabalin and the Glial Attenuator Minocycline on the Response to Intradermal Capsaicin in Patients with Unilateral Sciatica

    Article • PLoS ONE, June 2012, PLOS

    Mark Hutchinson

  74. Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence

    Article • Pharmacology & Therapeutics, May 2012, Elsevier

    Mark Hutchinson

  75. (+)-Naloxone, an Opioid-Inactive Toll-Like Receptor 4 Signaling Inhibitor, Reverses Multiple Models of Chronic Neuropathic Pain in Rats

    Article • Journal of Pain, May 2012, Elsevier

    Mark Hutchinson

  76. Morphine activates neuroinflammation in a manner parallel to endotoxin

    Article • Proceedings of the National Academy of Sciences, April 2012, Proceedings of the National Academy of Sciences

    Mark Hutchinson

  77. Toll-like receptors in chronic pain

    Article • Experimental Neurology, April 2012, Elsevier

    Mark Hutchinson

  78. Commentary on Landry et al.: “Propentofylline, a CNS glial modulator, does not decrease pain in post-herpetic neuralgia patients: In vitro evidence for differential responses in human and rodent microglia and macrophages”

    Article • Experimental Neurology, April 2012, Elsevier

    Mark Hutchinson

  79. Are the effects of alcohol on the CNS influenced by Toll-like receptor signaling?

    Article • Expert Review of Clinical Immunology, March 2012, Taylor & Francis

    Mark Hutchinson

  80. Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice

    Article • British Journal of Pharmacology, February 2012, Wiley

    Mark Hutchinson

  81. Early-Life Experience Decreases Drug-Induced Reinstatement of Morphine CPP in Adulthood via Microglial-Specific Epigenetic Programming of Anti-Inflammatory IL-10 Expression

    Article • Journal of Neuroscience, December 2011, Society for Neuroscience

    Mark Hutchinson

  82. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain

    Article • Brain Behavior and Immunity, October 2011, Elsevier

    Mark Hutchinson

  83. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains

    Article • Brain Behavior and Immunity, August 2011, Elsevier

    Mark Hutchinson

  84. Exploring the Neuroimmunopharmacology of Opioids: An Integrative Review of Mechanisms of Central Immune Signaling and Their Implications for Opioid Analgesia

    Article • Pharmacological Reviews, July 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Mark Hutchinson

  85. An MD2 Hot-Spot-Mimicking Peptide that Suppresses TLR4-Mediated Inflammatory Response in vitro and in vivo

    Article • ChemBioChem, June 2011, Wiley

    Mark Hutchinson

  86. Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment

    Article • Brain Behavior and Immunity, June 2011, Elsevier

    Mark Hutchinson

  87. Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain

    Article • Brain Behavior and Immunity, March 2011, Elsevier

    Mark Hutchinson

  88. A novel animal model of graded neuropathic pain: Utility to investigate mechanisms of population heterogeneity

    Article • Journal of Neuroscience Methods, October 2010, Elsevier

    Mark Hutchinson

  89. Application of a novel in silico high-throughput screen to identify selective inhibitors for protein–protein interactions

    Article • Bioorganic & Medicinal Chemistry Letters, September 2010, Elsevier

    Mark Hutchinson

  90. A new metabotropic glutamate receptor agonist with in vivo anti-allodynic activity

    Article • Bioorganic & Medicinal Chemistry, August 2010, Elsevier

    Mark Hutchinson

  91. Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity

    Article • Neuroscience, June 2010, Elsevier

    Mark Hutchinson

  92. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences

    Article • Neuroscience, May 2010, Elsevier

    Mark Hutchinson

  93. Toll-like receptor 4 in CNS pathologies

    Article • Journal of Neurochemistry, April 2010, Wiley

    Mark Hutchinson

  94. Evidence that opioids may have toll-like receptor 4 and MD-2 effects

    Article • Brain Behavior and Immunity, January 2010, Elsevier

    Mark Hutchinson

  95. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β

    Article • Neuroscience, January 2010, Elsevier

    Mark Hutchinson

  96. Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats

    Article • Neuroscience, December 2009, Elsevier

    Mark Hutchinson

  97. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

    Article • Expert Opinion on Pharmacotherapy, November 2009, Informa Healthcare

    Mark Hutchinson

  98. Enduring Reversal of Neuropathic Pain by a Single Intrathecal Injection of Adenosine 2A Receptor Agonists: A Novel Therapy for Neuropathic Pain

    Article • Journal of Neuroscience, November 2009, Society for Neuroscience

    Mark Hutchinson

  99. The “Toll” of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting Glia

    Article • Trends in Pharmacological Sciences, November 2009, Elsevier

    Mark Hutchinson

  100. Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence

    Article • Pharmacogenetics and Genomics, November 2009, Wolters Kluwer Health

    Mark Hutchinson

  101. The cortical innate immune response increases local neuronal excitability leading to seizures

    Article • Brain, June 2009, Oxford University Press (OUP)

    Mark Hutchinson

  102. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release

    Article • Brain Behavior and Immunity, May 2009, Elsevier

    Mark Hutchinson

  103. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)

    Article • Brain Behavior and Immunity, February 2009, Elsevier

    Mark Hutchinson

  104. A Peptide Antagonist of the TLR4-MD2 Interaction

    Article • ChemBioChem, January 2009, Wiley

    Mark Hutchinson

  105. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia

    Article • Brain Behavior and Immunity, November 2008, Elsevier

    Mark Hutchinson

  106. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia

    Article • Brain Behavior and Immunity, November 2008, Elsevier

    Mark Hutchinson

  107. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)

    Article • European Journal of Neuroscience, July 2008, Wiley

    Mark Hutchinson

  108. “Listening” and “talking” to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids

    Article • Brain Research Reviews, November 2007, Elsevier

    Mark Hutchinson

  109. Ibudilast (AV-411)

    Article • Expert Opinion on Investigational Drugs, June 2007, Informa Healthcare

    Mark Hutchinson

  110. Glia as the “bad guys”: Implications for improving clinical pain control and the clinical utility of opioids

    Article • Brain Behavior and Immunity, February 2007, Elsevier

    Mark Hutchinson

  111. The effects of a single exposure to uncontrollable stress on the subsequent conditioned place preference responses to oxycodone, cocaine, and ethanol in rats

    Article • Psychopharmacology, January 2007, Springer Science + Business Media

    Mark Hutchinson

  112. Air Pollution Distribution Patterns in the San Bernardino Mountains of Southern California: a 40-Year Perspective

    Article • The Scientific World JOURNAL, January 2007, Hindawi Publishing Corporation

    Mark Hutchinson

  113. Neuroimmune Interactions and Pain: The Role of Immune and Glial Cells

    Article • January 2007, Elsevier

    Mark Hutchinson

  114. Glia: novel counter-regulators of opioid analgesia

    Article • Trends in Neurosciences, December 2005, Elsevier

    Mark Hutchinson

  115. Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids

    Article • International Immunopharmacology, November 2005, Elsevier

    Mark Hutchinson

  116. (S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(−)-methadone

    Article • International Immunopharmacology, November 2004, Elsevier

    Mark Hutchinson

  117. In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance

    Article • Pain, August 2004, Wolters Kluwer Health

    Mark Hutchinson

  118. Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation

    Article • European Journal of Pharmacology, June 2004, Elsevier

    Mark Hutchinson

  119. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes

    Article • British Journal of Clinical Pharmacology, November 2003, Wiley

    Mark Hutchinson

  120. Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection1

    Article • Journal of Chromatography B, February 2003, Elsevier

    Mark Hutchinson

  121. Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studies

    Article • European Journal of Pharmacology, October 2002, Elsevier

    Mark Hutchinson

  122. The future: new concepts and potential therapies

    Article • Cambridge University Press

    Mark Hutchinson